Schwab, Matthias
Chan, Andrew
Eser, Anna-Katharina
Kallmann, Boris
Pöhlau, Dieter
Richter, Joachim
Wagner, Torsten B.
Grothe, Christoph
Funding for this research was provided by:
Merck Healthcare KGaA
Article History
Received: 12 September 2023
Accepted: 16 February 2024
First Online: 26 March 2024
Declarations
:
: Matthias Schwab has served on advisory boards for, and received funding for travel or speaker honoraria from Actelion-Janssen, Almirall, Bayer, Biogen, Bristol Myers Squibb, Celgene, Sanofi-Genzyme, Merck Healthcare, Novartis, Roche, and Teva, and received research support from Novartis and Bayer. Andrew Chan has served on advisory boards for, and received funding for travel or speaker honoraria from Actelion-Janssen, Almirall, Bayer, Biogen, Bristol Myers Squibb, Celgene, Sanofi-Genzyme, Merck Healthcare, Novartis, Roche, and Teva, all for hospital research funds; and research support from Biogen, Genzyme and UCB. Anna-Katharina Eser has no disclosures to declare. Boris-Alexander Kallmann has received honoraria for serving on advisory boards and as speaker from Merck Healthcare, Biogen, Genzyme, Teva, Roche, Novartis, Genesis Pharma, BMS, Janssen, Celgene, Biologix. Dieter Pöhlau has received speaking fees, travel support and financial support for research projects from Allmirall, Bayer, Biogen-Idec, Merck Healthcare, Octapharm, Novartis, Roche, Sanofi-Aventis and Teva. Joachim Richter is an employee of Merck Healthcare Germany, Weiterstadt, Germany. Torsten Wagner is an employee of Merck Healthcare Germany, Weiterstadt, Germany. Christoph Grothe has received speaking honoraria, travel compensations and fees for serving on advisory boards from Biogen, Merck Healthcare, Novartis, Sanofi, Roche, Boehringer Ingelheim, Teva as well as research grants from Novartis and Merck Healthcare.
: Ethical approval was received from the Ethics Committee of the Faculty of Medicine of the Ruhr University Bochum, 44789 Bochum on 17 January 2013. In accordance with the legal provisions in Germany (§ 67 subsection 6 of the German Medicinal Products Act), the competent authority, i.e., the German Federal Institute for Drugs and Medical Devices, confirmed that this approval covered all study centers. The German Association of Statutory Health Insurance Physicians and the German Federal Associations of Health Insurance Funds were notified. The provided information included the places, time, monitoring plan, and aim of the non-interventional study, the names of the participating physicians, again covering all study sites. This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. All patients provided informed consent (part of the ethic approval) to participate in the study.
: Permission for use of the Morisky Medication Adherence Scale was obtained from Morisky Medication Adherence Research, LLC.